invivoscribe®
Improving Lives with Precision Diagnostics®

Hematological Test Menu

	Disease	Gene Rearrangement							Translocation				Mutations	
	Recommended Primary Test / Recommended Secondary Test	IGH (V_H-J_H)	IGH (D_H-J_H)	IGK	IGL	IGHV SHM	TRB	TRD	TRG	IGH-BCL1 (CCND1)	IGH-BCL2	BCR-ABL1*	PML RARa*	FLT3	NPM1
Lymphoid/ Lymphoma	Marginal Zone Lymphoma (MZL), extranodal[12,13,27]	88%	58%	84%	29%		23%	10%	16%						
	Marginal Zone Lymphoma (MZL), nodal[13]	100%	30%	80%	30%		10%	20%	10%						
	Mantle Cell Lymphoma (MCL)[2,6,7,12,13,27,37]	100%	11%	100%	44%	*	9%	4%	11%	75%					
	Follicular Lymphoma (FL)[3,7,12,13,27,28]	84%	19%	84%	21%		6%	5%	2%		90%				
	Diffuse Large B-cell Lymphoma (DLBCL)[3,12,13,27]	80%	30%	80%	28%		21%	14%	15%		30%				
	Multiple Myeloma (MM) and other Plasma Cell Neoplasms (PCN)[2,9,10,20,25]	84%	60%	57%	97%					20%					
	Chronic Lymphocytic Leukemia (CLL)[11,12,13,15,23,27,35]	100%	43%	100%	30%	*	25%	12%	18%						
	B-cell Acute Lymphoblastic Leukemia (B-ALL)[4,12,14,19,21,22,27,29,30,31,32,33,34]	96%	57%	95%	20%		81%	86%	75%			30%			
	Suspect B-cell Proliferations[12,26,27,33]	93%	93%	90%	40%		20%		20%						
	Peripheral T-cell Lymphoma (PTCL)[12,13,14,24]	35%	4%		2%		98%		94%						
	T-cell Acute Lymphoblastic Leukemia (T-ALL)[12,14,21,22,29,31]	24%	25%	4%			92%	68%	95%						
	Angioimmunoblastic T-cell Lymphoma (AILT)[12,13,14]	19%	11%	30%	5%		99%	35%	92%						
	Adult T-cell Leukemia/Lymphoma[39]						97%		96%						
	Anaplastic Large-Cell Lymphoma (ALCL)[12,13,14]						74%	12%	74%						
	T-cell Prolymphocytic Leukemia (T-PLL)[12,13,14]	3%	3%	3%	3%		100%	6%	94%						
	T-cell Large Granular Lymphocytic Leukemia (T-LGL Leukemia)[12,13,14]			4%	4%		97%	29%	96%						
	Suspect T-Cell Proliferations[12,26,40]	10%		10%			90%	11%	90%						
Myeloid	Acute Myeloid Leukemia (AML)[8,16]													33%	64%
	Acute Promyelocytic Leukemia (APL)[1,5,16,17]												90%		
	Chronic Myeloid Leukemia (CML)[7,18,19,21,38]											87%			
	Myeloproliferative Neoplasms (MPNs)[38]											10%			

Note: The percentage of samples within a given disease category were detected using each gene target. Percentages indicate the highest referenced value.

invivoscribe®
Improving Lives with Precision Diagnostics®

PCR-based Ig/TCR Profiles with Combined Target Prevalence[26]

	n =	*IGH* (V_H- J_H)	*IGK*	*IGH + IGK*	*TCRB*	*TCRG*	*TCRB + TCRG*
MCL	54	100%	100%	100%	9%	11%	NE
CLL/SLL	56	100%	100%	100%	25%	18%	NE
FL	109	86%	84%	100%	6%	2%	NE
MZL*	41	95%	83%	100%	24%	15%	NE
DLBCL	109	85%	80%	98%	21%	15%	NE
T-PLL	33	9%	3%	NE	100%	94%	100%
T-LGL	28	0%	4%	NE	96%	96%	100%
PTCL-NOS	47	9%	2%	NE	98%	94%	100%
AIT	37	30%	19%	NE	89%	92%	95%
ALCL‡	43	2%	0%	NE	74%‡	74%‡	79%‡

*MZL comprises both extranodal (31) and nodal (10) cases.
‡The lower percentages in ALCL are partly caused by a series of nine null-type ALCL without any TCR gene rearrangements.

References

1. Kakizuka, A et al. (1991) *Cell*, 66:675-684.
2. Rimokh, R et al. (1994) *Blood*, 83:1871-1875.
3. Gribben, JG et al. (1994) *Blood*, 83:3800-3807.
4. Radich, JP et al. (1994) *Leukemia*, 8:1688-1695.
5. Gallagher, RE et al. (1995) *Blood*, 86:1540-1547.
6. De Boer, CJ et al. (1995) *Blood*, 86:2715-2723.
7. Deininger, MW et al. (2000) *Blood*, 96:3343-56.
8. Schlenk RF et al. (2008) *N Engl J Med.*, 358:1909-1918.
9. Gonzalez, D et al. (2003) *Leukemia*, 17:1051-1057.
10. Gonzalez, D et al. (2003) *Leukemia*, 17:1398-1403.
11. Ghia, P et al. (2007) *Leukemia*, 21:1-3.
12. van Krieken, JH et al. (2007) *Leukemia*, 21:201-6.
13. Evans, PAS et al. (2007) *Leukemia*, 21:207-214.
14. Bruggemann, M et al. (2007) *Leukemia*, 21:215-221.
15. Davi, F et al. (2008) *Leukemia*, 22:212-214.
16. Döhner, H et al. (2010) *Blood*, 115:453-474.
17. Huang, W et al. (1993) *Blood*, 82:1264-1269.
18. Hughes, T et al. (2006) *Blood*, 108:28-37.
19. Westbrook, CA et al. (1992) *Blood*, 80:2983-2990.
20. Ralph, QM et al. (1993) *Blood*, 82:202-20.
21. Juárez-Velázquez, MR et al. (2013) *Clinical Epidemiology of Acute Lymphoblastic Leukemia - From the Molecules to the Clinic*, 193-235.
22. Raimondi, S. (2007) *Atlas Genet Cytogenet Oncol Haematol.*, 11(4):328-339.
23. Vardi, A et al. (2015) *Clin Cancer Res.*, 22(1):167-174.
24. Tan, BT et al. (2008) *J Mol Diag.*, 10(6):502–512.
25. González, D et al. (2007) *Blood*, 110:3112-3121.
26. Langerak AW et al. (2007) *Exp Opin Med Diag.*, 1(4):451-461.
27. Arcila, ME et al. (2019) J *Mol Diag.*, 2: 330-341.
28. Campo, E et al. (2011) *Blood*, 117(19): 5019–5032.
29. Smirnova, SY et al. (2016) *Acta naturae*, 8(4):100–109.
30. Szczepanski, T et al. (2001) *Leukemia*,15:1415–1423.
31. Szczepanski, T et al. (1998) *Leukemia*, 12:1081–1088.
32. Beishuizen, A et al. (1994) *Leukemia*, 8(12):2228-36.
33. Tümkaya T et al. (2001) *Leukemia*, 15:121–127.
34. Felix, CA et al. (1990) *J Clin Oncol.*, 8(3):431-42.
35. Rosenquist R et al. (2017) *Leukemia*, 31:1477–1481.
36. Arons, E et al. (2011) *Blood*, 117(18): 4844–4851.
37. Lai, R et al. (2006) *Modern Pathology*, 19:1498–1505.
38. Srour SA et al. (2017) *Br J Haematol.*, 177(2): 331.
39. Ohshima, K et al. (1990) *Hematol Oncol.*, 8(2):111-8.
40. van Dongen, JJM et al. (2003) *Leukemia*, 17, 2257–2317.

M-0017 Rev02 July 2020

Invivoscribe® is dedicated to Improving Lives with Precision Diagnostics® worldwide by providing high quality, reliable, cutting-edge tools for molecular biology and molecular diagnostics.

IdentiClone® Assays
Gel/ABI

- CE-IVD
- BIOMED-2 design
- Assays for B- and T-cell clonality assessment & Somatic Hypermutation (SHM) Assay
- High sensitivity
- Design supports low or high throughput
- Easy interpretation

LymphoTrack® Dx Assays
NGS

- CE-IVD
- One-step PCR for library generation
- Identify, track, and assess mutation status of B- and T-cell gene rearrangements
- Sequence amplicons from any LymphoTrack Dx kit together
- Available for Illumina® MiSeq® and Thermo Fisher Scientific® Ion S5™ and PGM™ platforms
- Bioinformatics software included for easy analysis and interpretation

invivoscribe.com | Tel +1 858.224.6600 | Fax +1 858.224.6601 | Email marketing@invivoscribe.com | 10222 Barnes Canyon Road, Bldg. 1 | San Diego, CA 92121